Once again, we are privileged to share the acknowledgment that APICES has received in the recent publication titled “Phase II clinical trial of nab‑paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study”  published in Cancer Chemotherapy and Pharmacology and related with one study conducted by APICES, which has collaborated in several tasks of it.  During the development of this study, APICES has participated in the study design, setup, coordination and project management, monitoring, statistical analysis, medical writing and publication assistance. We would like to thank Guillermo López-Vivanco and Jaime Feliu for the opportunity to participate on this study and to have made it possible. This means an extra motivation to all APICES team in order to give continuity to the implication we have in every project in which we collaborate. We hope to keep participating in conduct projects as until now and that our work continue improving the patients quality of life.

This trial has the aim to evaluate the quality of life, global health status and deterioration-free survival of an elderly population with unresectable locally advanced or metastatic pancreatic cancer treated with nab-paclitaxel in combination with gemcitabine.

You can find the publication in the following link:

BIBABRAX Study